Stockscreener 앱 받기
20.36
2.16%
0.43
전일 마감가:
$19.93
열려 있는:
$19.96
하루 거래량:
1.94M
Relative Volume:
1.79
시가총액:
$1.70B
수익:
-
순이익/손실:
$-230.32M
주가수익비율:
-5.7744
EPS:
-3.5259
순현금흐름:
$-196.04M
1주 성능:
+7.44%
1개월 성능:
+16.41%
6개월 성능:
+10.11%
1년 성능:
-58.35%
1일 변동 폭
$19.70
$21.28
1주일 범위
$18.46
$21.28
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
20.36 | 1.70B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 업그레이드 | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics' CFO Sells 39K Shares - The Motley Fool
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
Insider Sell: Santos da Silva Jorge Sells 47,775 Shares of MoonL - GuruFocus
CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan - Stock Titan
Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (M - The National Law Review
MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa - Dermatology Times
Top biotech stocks to watch in second half of 2026, says Clear Street - Investing.com South Africa
MLTX Maintained by Leerink Partners -- Price Target Raised to $2 - GuruFocus
Leerink raises Moonlake stock price target on HS drug data By Investing.com - Investing.com South Africa
Leerink raises Moonlake stock price target on HS drug data - Investing.com
Form 144 MoonLake Immunotherapeutics For: 30 June By Investing.com - Investing.com South Africa
MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026) - Stock Titan
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa - Yahoo Finance
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? - Stocktwits
Form 13D/A MoonLake Immunotherapeutics For: 29 June By Investing.com - Investing.com South Africa
BVF group reports 19.7% MoonLake Immunotherapeutics (MLTX) stake - Stock Titan
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Chart - ChartMill
MoonLake Immunotherapeutics (MLTX) Is Down 10.2% After $200M Follow-On Offering To Fund Sonelokimab PushHas The Bull Case Changed? - simplywall.st
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Ove - The National Law Review
MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares - Global Legal Chronicle
Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi - The National Law Review
Join Class Action to Recover Losses from MoonLake Immunotherapeut - The National Law Review
Levi & Korsinsky Urges MoonLake (MLTX) Shareholders to Act Before Lead Plaintiff Deadline December 15, 2025 - The National Law Review
MoonLake Immunotherapeutics (MLTX) Investigation: Bronstein, Gewi - The National Law Review
Securities Fraud Class Action Filed Against MoonLake Immunotherap - The National Law Review
Recover Investment Losses: Class Action Initiated Against MoonLake Immunotherapeutics (MLTX) - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating MoonLake Immu - The National Law Review
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Acti - The National Law Review
Shareholders of MoonLake Immunotherapeutics (MLTX): Protect Your - The National Law Review
MLTX ALERT: Block & Leviton LLP Announces The Filing of a Class A - The National Law Review
10 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
MoonLake Immunotherapeutics (MLTX) LawsuitInvestors Urged to C - The National Law Review
Levi & Korsinsky Invites Investors to SueWallSt After MoonLake Immunotherapeutics Stock Collapse - The National Law Review
MLTX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
MLTX stock extends pullback after biggest rally in over 6 months following skin disease trial data — a look at the latest development - MSN
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday - AOL.com
MoonLake Immunotherapeutics Class A Actuals & Estimates (NASDAQ:MLTX) - TradingView
Why MoonLake Immunotherapeutics stock wilted on Wednesday - MSN
(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics prices $200M public offering of Class A shares - MSN
Enterprise value to EBIT forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
MoonLake Expects Offering to Close on or About June 25 >MLTX - Moomoo
United StatesMintz Advises On MoonLake Immunotherapeutics’ $200 Million Public Offering - Mondaq
Enterprise value to EBIT forward of MoonLake Immunotherapeutics – BOATS:MLTX - TradingView
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):